



Partner

Paris | 32 rue de Monceau, Paris, France 75008

T +33 1 57 57 82 82 | F +33 1 57 57 80 81

alain.decombe@dechert.com

Services

Corporate > Mergers and Acquisitions > Life Sciences >
Energy and Natural Resources > Private Equity > Digital Health >

Alain Decombe, Deputy Chair for International Operations, Managing Partner of the Paris office and a member of the firm's Policy Committee, has advised on numerous strategic M&A transactions.

Mr. Decombe advises on all types of corporate transactions, both in France and internationally. He is well-known for his ability to structure and negotiate complex deals in a practical and business-oriented manner, and lead them to successful conclusions. Mr. Decombe regularly advises multinational corporations and private equity funds with respect to their investments in many industry sectors, mostly life sciences, but also food, industrial gases and highly engineered products.

Mr. Decombe is recommended for his corporate M&A and pharma/life sciences work in France by *Chambers Europe* 2018, where he is admired by clients for his "very high-level" work on large-scale transactions in this sector. He is also recommended in *Chambers Global* 2018 in France: Corporate/M&A. He is noted by clients as "incredibly smart and responsive" and credited for his "great market understanding" in *The Legal 500 EMEA* 2018, where he is recognized as leading individual for his work in healthcare and life sciences in France.

In addition, he is recognized as a leading lawyer by *Who's Who Legal* 2019 for Life Sciences in France and by *The Best Lawyers™ in France* 2019 in biotechnology, life sciences and corporate law. *IFLR1000* 2019 recommends Mr. Decombe in its M&A and private equity categories and is named by *Décideurs* as one of the top 50 lawyers in France.

Mr. Decombe joined Dechert in 2005. He began his career in British and American global law firms. He became a partner of one of those firms in 1995 and took on managing functions for the first time in 2002.

EXPERIENCE

- **A British pharmaceutical group** in an exchange of strategic assets and the creation of a joint-venture with a Swiss pharmaceutical group.
- **A U.S. Fortune 500 group** in its €150 million acquisition of a French leading group in security monitoring systems from financial sponsors.
- **A CAC 40 group** in its acquisition of an international group specializing in the supply of industrial gases.
- **A sovereign state**, as stakeholder in a CAC 40 company, on a £21 billion acquisition of a European industrial company.

Life Sciences

- **A leading international brand name in pet care and wellness** in the purchase of a pet care accessories, rawhides and veterinary medicines business in France, Italy and Spain.
- **A Sino-French venture capital fund** on its investment in a French Contract Manufacturing Organization specialized in pharmaceutical development and the manufacture of high value-added sterile products.
- **The world's leading provider of non-invasive medical devices dedicated to the assessment of chronic liver diseases** on a minority investment from a Sino-French venture capital fund and a US venture capital fund.
- **A leading pharmaceutical company** in the implementation of several strategic assets transactions in France with a Swiss pharmaceutical company.
- **The shareholders of a French biotechnology company** in the sale of 100% of the shares of the company to a Swiss pharmaceutical group.
- **A French investment company** in the acquisition of a French biotechnology company through a LBO structure.
- **A leading French pharmaceutical company** in the acquisition of a group of French health services companies.
- **An American pharmaceutical and medical device group** in the €170 million purchase of one of its major French suppliers.
- **One of the largest hospital management groups in the United States** on its €320 million sale of one of France's largest networks of clinics to private equity funds.
- **The shareholders of a French pharmaceutical group** in its US\$450 million sale to an American biopharmaceutical company.
- **The shareholders of the fourth largest independent French pharmaceutical group** in its €195 million sale to an Indian pharmaceutical group.

EDUCATION

- Université Paris 2 Panthéon-Assas, DESS, Advanced Specialized Studies in Business and Tax Law, 1985

- UCLA School of Law, LL.M., 1988

ADMISSIONS

- Paris

LANGUAGES

- English
- French

SPEAKING ENGAGEMENTS

- **The Inside Counsel Revolution** - Paris, France (April 20, 2016)